A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency
Latest Information Update: 05 Oct 2021
At a glance
- Drugs Catridecacog (Primary)
- Indications Factor XIII deficiency
- Focus Registrational; Therapeutic Use
- Sponsors Novo Nordisk
- 27 Dec 2013 New trial record
- 23 Dec 2013 The US FDA approved Tretten for the treatment of congenital factor XIII A-subunit deficiency based on results from a clinical programme, including this trial.